Arkema’s Specialty Shield Holds—but the Acrylics Floor Is Still Creaking
Q3 EBITDA rose 7% and guidance held, yet the real story is a quiet mix shift into UV curing, rheology and a first-quartile China acrylics site while Europe construction refuses to turn.
AKE.PA · Earnings Call · 2026-11-05
The headline is fine. The mix is the story.
Arkema’s third-quarter release reads like a victory of portfolio engineering over a bad chemical tape. Sales rose 8.1% to €2.4 billion, EBITDA rose 7% to €332 million, and adjusted EPS jumped 23% to €1.23. Management kept full-year guidance for EBITDA slightly above last year at constant currency—no small thing given that the original guide predated the Middle East conflict. But the volume line is the tell: group volumes rose only 0.6%, Specialty Materials volumes rose 1.7%, and Primary Materials volumes fell 5.1% on weak acrylic monomers. “Sales grew materially by 8% year-on-year, supported by the price effect” — Thierry Le Hénaff, Chairman and Chief Executive Officer · 2026-11-05, Thierry Le Hénaff said, with North America around 36% of group sales. That is a price-and-mix quarter, not a demand recovery. The macro backdrop is familiar from the global keyword tape: Middle East conflict, energy cost inflation, logistics and raw materials all rose over the summer. Arkema is not unique in facing that. What is more company-specific is how much of the EBITDA now comes from specialty lines—90% of group EBITDA—and how little help acrylics provided. The CEO noted the absence of “the acrylic support we saw in Q2.” Europe construction did not turn. “No, so far, we don't see really any change in trend in Europe. We see that interest rates are increasing” — Thierry Le Hénaff, Chairman and Chief Executive Officer · 2026-11-05, he said, adding that adhesives growth came from industrial, not construction. That matters because the market has been waiting for a European construction recovery for several quarters.What actually changed: coatings, rheology and UV curing
The freshest signal is inside Coating Solutions. EBITDA there rose 23%, and the driver was not a sudden bounce in paint volumes. It was the high-value additive portfolio—rheology modifiers and UV curing products—sold into electronics, 3D medical and semiconductor applications. This is a new emphasis for Arkema’s call narrative. The prior four quarters talked about coatings mainly through the acrylic upstream/downstream split, net pricing and low-cycle conditions. On this call, management explicitly extended the rheology story into UV curing: “our UV curing supported by electronics, 3D medical, semiconductor has really accelerated that growth this year” — Thierry Le Hénaff, Chairman and Chief Executive Officer · 2026-11-05. That is a company-unique innovation angle, not sector boilerplate. It also explains how coatings can grow while construction is flat: the end market is less about new buildings and more about electronic miniaturization and specialty applications. Advanced Materials was roughly stable, with High Performance Polymers benefiting from batteries, cables and consumer goods, while Performance Additives suffered from the Middle East situation. The polyamide and PVDF franchise is doing the quiet work: Polyamide 11 reached record production in Singapore, and the new U.S. PVDF capacity started at the end of Q2 just as LFP battery demand—good for Arkema’s technology—continued to outgrow NMC. The CEO would not comment on the European PVDF anti-dumping investigation, but he was clear that Arkema’s PVDF volumes and technology position remain strong. This is the same battery and lightweighting story from prior calls, now with more commercial traction.The China acrylics card
The most underappreciated item may be the China acrylics site. Arkema just completed a process transformation there, and the CEO called it a breakthrough: “the site is really working well, and it was a breakthrough technology” — Thierry Le Hénaff, Chairman and Chief Executive Officer · 2026-11-05. He said the site is now in the first quartile on competitiveness, helped by world-scale size and the new process. In low-cycle conditions, EBITDA from that site is “more single digit,” but the optionality is real: if acrylic spreads normalize, this is a cash generator rather than a drag. That connects directly to terms of competitiveness, a top-five keyword on this call. For years, acrylics have been the bear case—too cyclical, too European, too exposed to Chinese supply. The China transformation does not fix the cycle, but it changes the cost position. That is a genuine strategic shift, even if management refuses to trumpet it. The major projects are also progressing, but slower. Arkema expects €50 million of incremental EBITDA from major projects in 2026, down from €60 million last year; in a normal macro, the pace would be closer to €100 million a year. The long-term €400 million target by 2028 remains, but the timing depends on recovery. “In the current kind of macro context, we are more at 50, 60 last year, we were at EUR 60 million this year EUR 50 million” — Thierry Le Hénaff, Chairman and Chief Executive Officer · 2026-11-05, the CEO said. The Nutrien project is already contributing, with a significant ramp expected next year. This is a “show me” story: the projects are strategically valid, but the payback is deferred.The caution premium
The tension on this call is stylistic and substantive. Analyst Chetan Udeshi pressed management on why peers sound more upbeat on order books. Le Hénaff did not take the bait. He said Arkema has always been cautious, and then delivered the line of the call:That is consistent with the prior calls. In February, he said Europe had “certainly reached a bottom” but warned Arkema had been “caught several times by surprise.” In November 2025, he said: “I don't know if we are at the bottom, but we get close to the bottom. And what we cannot say is when the recovery will start.” — Thierry Le Hénaff, Chairman and Chief Executive Officer · 2025-11-07 The wait-and-see has been running for several quarters. So when management refuses to call a turn now, it is not new information—it is the same cautious regime. The difference is that this time the specialty mix is carrying the numbers while acrylics and construction lag. The balance sheet explains the caution. Net debt and hybrids were €3.5 billion, including €800 million of hybrids, with net debt/EBITDA around 2.8x. Inflation is expected to add about €150 million to working capital this year, though Q4 seasonality should release cash and bring leverage down a little. CapEx will be below €600 million, and management is comfortable beating that guide. The hedge book is the unsung hero: energy is only 6-7% of variable costs, electricity in Europe is nearly 100% hedged or at least 80%, and total energy is at least 50% hedged. “on the whole energy cost of Arkema, I would say we are hedged at least a good 50%” — Thierry Le Hénaff, Chairman and Chief Executive Officer · 2026-11-05. That is why Arkema could hold guidance while energy cost inflation hit European chemicals. There is also a strategy question that will not go away. Chetan asked why Arkema is the best owner of Adhesives, given the mix and the multiple versus pure-play peers. The CEO’s answer was unequivocal: adhesives are “a clear pillar of our Specialty Material strategy,” integrated with Advanced Materials and Coatings. He pointed to the Bostik acquisition and the upgraded portfolio. That is the same defense management has given for several quarters. It may be right, but the market has not rewarded the conglomerate structure. The Q3 print does not settle that debate.I think everybody has a different style of communication... we have always a cautious communication, and we'll continue to do so. But results and facts are facts and results are results.